LIMXOTCServices-Miscellaneous Amusement & RecreationUS GAAP · USD

Limitless X Holdings Inc.

Limitless X Holdings Inc. is a U.S.-based consumer products and brand licensing company centered on nutritional supplements and related wellness products. Its business has included manufacturing and distributing licensed products under agreements tied to brands controlled by its CEO, with recent disclosures showing a narrower focus on the NZT-48 supplement line after other licensed product lines were discontinued.

Kysy yhtiöstä
Liikevaihto0,9milj. USD
−71,8 %v/v
Liikevoitto (EBIT)−9,1milj. USD
−134,5 %v/v
EBIT-marginaali−961,8%
−846,1 %-yks.v/v
Nettotulos−46,1milj. USD
−997,3 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−2002040milj. USD2020: 0,02 milj. USD2020: EBIT −0,28 milj. USD20202021: 0,34 milj. USD2021: EBIT −0,17 milj. USD20212022: 40 milj. USD2022: EBIT −17 milj. USD20222023: 15 milj. USD2023: EBIT −6,3 milj. USD20232024: 3,4 milj. USD2024: EBIT −3,9 milj. USD20242025: 0,95 milj. USD2025: EBIT −9,1 milj. USD20250,95−9,1
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Limitless X Holdings Inc.

Liiketoiminta

Osuus liikevaihdosta
Nutritional supplements70 %

Dietary and wellness supplement products sold under the company's branded and licensed portfolio.

Licensed consumer products20 %

Products manufactured and distributed under third-party or related-party brand licenses.

Royalty and licensing arrangements10 %

Revenue-linked commercialization rights and royalty economics tied to licensed brands.

Asiakkaat

The company sells to consumers seeking nutritional and wellness products, typically through branded consumer channels rather than enterprise customers. Its commercial model also depends on licensors and related-party brand owners, since product rights and royalty terms shape what can be manufactured and distributed.

End consumers

Buy supplements such as NZT-48 for personal wellness, convenience, and brand appeal.

Brand licensors

Provide product rights and receive royalties; they determine which products can be sold.

Retail and distribution channels

Purchase or carry the company's consumer products to reach final shoppers.

Strategia

Recent disclosures suggest a strategy of narrowing the product portfolio and concentrating on the NZT-48 supplement line after discontinuing other licensed gummy products. The company also appears focused on simplifying its licensing structure and resolving related-party royalty balances, which can reduce operational complexity and improve control over the remaining product set.

Focus on core supplement productsLyhyt aikaväli

A narrower portfolio can improve execution, inventory control, and brand focus.

Rationalize licensing and royalty structureLyhyt aikaväli

Lower complexity may reduce disputes, cash leakage, and related-party friction.

Maantiede

The available filings do not disclose a meaningful country-by-country revenue split, so the business profile is best understood as U.S.-centric. As a U.S. reporting company, its operating, legal, and financing activities are anchored in the United States, while product sales may extend through consumer distribution channels not separately broken out in the excerpts.

Riskit

The company faces concentration risk because its product set has been narrowed and its commercial rights depend on a small number of license agreements. It also has related-party exposure, royalty obligations, and a history of dividend waivers and offsets, which can complicate governance, cash flow, and financial reporting. As a consumer wellness business, it is also exposed to demand volatility, product acceptance risk, and regulatory scrutiny over supplement claims and manufacturing quality.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Related-party dependence1License and royalty risk2
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Related-party dependenceVaikutus: KorkeaTodennäköisyys: Korkea

    Key licenses and preferred stock holders are tied to the CEO or CEO-controlled entities.

    KohdistuuGovernancePricingTransaction fairness
  2. License and royalty riskVaikutus: KorkeaTodennäköisyys: Matala

    The company needs valid license rights to manufacture and distribute products.

    Kohdistuu: Commercial rights and gross margin structure

  3. Product concentrationVaikutus: Korkea

    The portfolio has been narrowed to NZT-48 and a limited set of remaining products.

    Kohdistuu: Revenue and brand dependence on one core product line

  4. Consumer demand and regulatory riskVaikutus: Keskitaso

    Supplement sales depend on consumer acceptance and compliance with product rules.

    KohdistuuSales volatilityRecallsMarketing restrictions
Kysy Clarifolta: Limitless X Holdings Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for product sales

Consumer product revenue depends on shipment, returns, and allowance estimates.

Vaikutus: Affects reported sales timing and net revenue

Royalty accruals and license obligations

The company pays royalties on gross sales under license agreements.

Vaikutus: Affects gross margin and accrued liabilities

Inventory returns and license termination accounting

Returned inventories were valued and offset against related balances.

Vaikutus: Affects inventory, receivables, and settlement gains/losses

Preferred stock dividend accruals and waivers

Accrued dividends on Series D Preferred Stock were waived by holders.

Vaikutus: Affects equity, liabilities, and related-party disclosures

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Healthier Choices Management Corp.

HCMC · Tobacco Products

China Foods Holdings Ltd.

CFOO · Medicinal Chemicals & Botanical Products

Goldenwell Biotech, Inc.

GWLL · Food and Kindred Products

LFTD Partners Inc.

LIFD · Pharmaceutical Preparations

CTT Pharmaceutical Holdings, Inc.

CTTH · Pharmaceutical Preparations

X4 Pharmaceuticals, Inc

XFOR · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026